Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
PharmX TechnologiesASX:PHX +5.00%32 6-1 Month Momentum % is -21.43% as of Aug. 20, 2026. GuruFocus rates ASX:PHX with a GF Score™ of 32/100 and a GF Value™ of A$0.07 (Significantly Overvalued). The stock has 3 warning signs investors should review. Among 673 Healthcare Providers & Services companies, PharmX Technologies ranks worse than 66.12% on this metric.
6-1 Month Momentum % is the total return of the stock from 6-month ago to 1-month ago. As of today (2026-08-20), PharmX Technologies's 6-1 Month Momentum % is -21.43%.
The industry rank for PharmX Technologies's 6-1 Month Momentum % or its related term are showing as below:
ASX:PHX's 6-1 Month Momentum % is ranked worse than 66.12% of 673
companies
in the Healthcare Providers & Services industry
Industry Median: -8.21
vs ASX:PHX: -21.43
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 6-1 Month Momentum % measures the total return to a stock over the past six months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
PharmX Technologies 6-1 Month Momentum % Related Terms
ASX:PHX vs VEEV, BTSG, HQY: 6-1 Month Momentum % Comparison
For the Health Information Services subindustry, PharmX Technologies's 6-1 Month Momentum %, along with its competitors' market caps and 6-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PharmX Technologies 6-1 Month Momentum % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, PharmX Technologies's 6-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where PharmX Technologies's 6-1 Month Momentum % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PharmX Technologies (ASX:PHX) has a 6-1 Month Momentum % of -21.43% as of Aug. 20, 2026. 6-1 Month Momentum measures the total return of the stock from 6-month ago to 1-month ago. View historical data on PharmX Technologies and its competitors. According to the industry distribution chart, PharmX Technologies ranks #445 out of 673 companies in the Healthcare Providers & Services industry, placing it in the top 66.1%.
Is PharmX Technologies' 6-1 Month Momentum % too high?
PharmX Technologies' current 6-1 Month Momentum % is -21.43%. Based on the distribution chart, PharmX Technologies ranks #445 out of 673 companies in the Healthcare Providers & Services industry, which is below the industry midpoint. Overall, PharmX Technologies has a GF Score™ of 32/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does PharmX Technologies' 6-1 Month Momentum % compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, PharmX Technologies ranks #445 out of 673 companies for 6-1 Month Momentum %. This places PharmX Technologies in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 6-1 Month Momentum % for a Healthcare Providers & Services company?
A good 6-1 Month Momentum % depends on the Healthcare Providers & Services industry context. However, 6-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 6-1 Month Momentum % mean?
A high 6-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 6-1 Month Momentum measures the total return of the stock from 6-month ago to 1-month ago. View historical data on PharmX Technologies and its competitors. PharmX Technologies's current 6-1 Month Momentum % is -21.43%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PharmX Technologies stock overvalued right now?
Based on GuruFocus' analysis, PharmX Technologies (ASX:PHX) is currently considered Significantly Overvalued. The stock's GF Value™ is A$0.07, compared to a current price of A$0.11 — trading 50% above its estimated fair value. The current 6-1 Month Momentum % is -21.43%. PharmX Technologies' overall GF Score™ is 32/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 6-1 Month Momentum % calculated?
6-1 Month Momentum % is calculated from a company's financial statements. For PharmX Technologies (ASX:PHX), the current 6-1 Month Momentum % is -21.43% as of Aug. 20, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is PharmX Technologies (ASX:PHX) Overvalued in 2026?
Based on GuruFocus' analysis, PharmX Technologies stock appears to be overvalued.
The current stock price of A$0.11 is trading 50% above its estimated GF Value™ of A$0.07.
GuruFocus considers PharmX Technologies to be Significantly Overvalued.
Key valuation signals for ASX:PHX:
6-1 Month Momentum %: -21.43%
GF Value™: A$0.07 vs. price of A$0.11 (50% above fair value)
No single metric tells the full story. See the ASX:PHX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
PharmX Technologies Ltd is an Australia-based software and technology company. The company has a single segment which is Health Services. In Health services, the company develops and distributes business software for the pharmacy industry with particular emphasis on point-of-sale and pharmaceutical dispensing software, support services, and associated computer hardware. It derives a majority of its revenue from the Health services business.
32GF Score
Get the complete analysis for ASX:PHX
6-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:PHX has been successfully added to your 
